Marker Therapeutics MRKR
NASDAQ MRKR
$1.05 -0.02 (-1.87%)
At close: Oct 1, 2026 · 4:00 PM EDT

Marker Therapeutics (MRKR) Operating Interest Expenses (2013 - 2014)

Updated

Marker Therapeutics' Operating Interest Expenses came in at $35,269 for Q1 2014, down 89.5% from $334,888 a year earlier.

Analysis

Marker Therapeutics (MRKR) Operating Interest Expenses (2013 - 2014) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Interest Exp. (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Marker Therapeutics 17.87 Mn -42.04 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2014 35,269.00
Mar 31, 2013 334,888.00
API Access

Marker Therapeutics Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-interest-expenses&ticker=MRKR&period=max&api_key=YOUR_API_KEY